Scott E. Deeter, Chief Executive Officer, and Mark Stathos, Ph.D., Director of Cell Biology, have published a scientific review examining what it will take to move an rVSV-vectored Bundibugyo ebolavirus vaccine from preclinical proof of concept into a product that survives manufacture, freezing, thaw, and delivery in the field. The review arrives during an urgent …
Recombinant albumin is the only stabilizing excipient in the licensed ERVEBO® vaccine — and the same formulation decisions are being made right now for Bundibugyo candidates. The filovirus virion: a fragile, host-cell-derived lipid bilayer studded with glycoprotein trimers — and the biophysical problem every rVSV-vectored vaccine formulation has to solve. Publication Details Publication Title: Translating …
Register Now Why Attend This Webinar? Understand how animal component-free rHSA can reduce variability and support more defined cell therapy manufacturing workflows. See how rHSA performs in iPSC, T cell, and MSC cryopreservation models, including post-thaw outcomes beyond viability. Learn how recombinant albumin compares with plasma-derived albumin in purity, consistency, and supply security. Get practical …
Introduction Our partner Evonik has published a detailed interview featuring InVitria’s Director of Business Development, Jake Hanks. The discussion focuses on how recombinant human serum albumin helps biopharma manufacturers reduce risks in cell therapy production through greater consistency, purity, and supply security. Full Interview Link Read the complete Evonik interview Partnership Overview Evonik distributes InVitria’s …
InVitria has joined the NSF Engineering Research Center for Cell Manufacturing Technologies (CMaT) as an industry member. The partnership brings together CMaT’s leadership in cell manufacturing research with InVitria’s expertise in animal-origin-free recombinant proteins to support consistent, scalable cell therapy manufacturing. CMaT works to transform the manufacture of cell-based therapeutics into large-scale, reproducible, and high-quality …
